China's Sanyou Bio Launches Comprehensive Monkeypox Product Line

Overview

Sanyou Biopharmaceuticals (Shanghai) has announced the launch of a comprehensive product line targeting monkeypox, which includes antigens, monoclonal antibodies, and overexpression cell lines.

Product Under 3 Categories

This product line features 65 items across three main categories: 

• 26 natural epitope antigens, 
• 28 high-affinity, 
• high-specificity monoclonal antibodies and 11 overexpression cell lines. 

These products target multiple key sites on the surface of monkeypox virus, including A29L, M1R, H3L, E8L, A35R, B6R, and critical sites such as A28L, A30L, B21R, L1R and I1L, which are vital for viral infection and assembly.

Monoclonal Antibodies

• Developed using Sanyou Bio's proprietary ""over-trillion innovative antibody discovery"" platform, the monoclonal antibodies span multiple species, including fully human, nano, and mouse antibodies. 
• These antibodies are essential for therapeutic drug development, with high-affinity nano antibodies being particularly valuable for structural analysis and bispecific research. 
• Additionally, the entire range of antibodies, natural epitope antigens, and overexpression cell lines can be utilized in diagnostic reagents and scientific research.

Words from CEO: Sanyou Bio

• Dr Lang Guojun, CEO of Sanyou Bio, emphasised the company's rapid response capabilities, citing significant contributions during the COVID-19 pandemic. During that time, Sanyou Bio played a key role in the drug discovery and preclinical development of two innovative COVID-19 antibody therapies, which were published in leading journals such as Science and Cell Research, with related therapeutics advancing to clinical trials. 
• With this new monkeypox product line, Sanyou Bio aims to strengthen the development of vaccines, therapeutics, diagnostic tools and research initiatives, furthering its commitment to global public health.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!